Table of Contents Author Guidelines Submit a Manuscript
Autoimmune Diseases
Volume 2012, Article ID 357101, 6 pages
http://dx.doi.org/10.1155/2012/357101
Review Article

Anti-Integrin Therapy for Multiple Sclerosis

1Emergency and Critical Care Center, Mie University Hospital, 2-174 Edobashi, Tsu 514-8507, Japan
2Departments of Molecular Pathobiology and Cell Adhesion Biology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu 514-8507, Japan

Received 10 August 2012; Revised 28 November 2012; Accepted 28 November 2012

Academic Editor: Ricard Cervera

Copyright © 2012 Eiji Kawamoto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. M. Frohman, M. K. Racke, and C. S. Raine, “Medical progress: multiple sclerosis—the plaque and its pathogenesis,” New England Journal of Medicine, vol. 354, no. 9, pp. 942–955, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. B. D. Trapp and K. A. Nave, “Multiple sclerosis: an immune or neurodegenerative disorder?” Annual Review of Neuroscience, vol. 31, pp. 247–269, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Steinman, “A molecular trio in relapse and remission in multiple sclerosis,” Nature Reviews Immunology, vol. 9, no. 6, pp. 440–447, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Naci, R. Fleurence, J. Birt, and A. Duhig, “Economic burden of multiple sclerosis: a systematic review of the literature,” PharmacoEconomics, vol. 28, no. 5, pp. 363–379, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Goverman, “Autoimmune T cell responses in the central nervous system,” Nature Reviews Immunology, vol. 9, no. 6, pp. 393–407, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. R. M. Ransohoff, “Natalizumab for multiple sclerosis,” New England Journal of Medicine, vol. 356, no. 25, pp. 2622–2629, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. B. H. Luo, C. V. Carman, and T. A. Springer, “Structural basis of integrin regulation and signaling,” Annual Review of Immunology, vol. 25, pp. 619–647, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. R. O. Hynes, “Integrins: bidirectional, allosteric signaling machines,” Cell, vol. 110, no. 6, pp. 673–687, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. J. A. Askari, P. A. Buckley, A. P. Mould, and M. J. Humphries, “Linking integrin conformation to function,” Journal of Cell Science, vol. 122, no. 2, pp. 165–170, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Shimaoka, J. Takagi, and T. A. Springer, “Conformational regulation of integrin structure and function,” Annual Review of Biophysics and Biomolecular Structure, vol. 31, pp. 485–516, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Moser, K. R. Legate, R. Zent, and R. Fässler, “The tail of integrins, talin, and kindlins,” Science, vol. 324, no. 5929, pp. 895–899, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Evans, I. Patzak, L. Svensson et al., “Integrins in immunity,” Journal of Cell Science, vol. 122, no. 2, pp. 215–225, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. D. M. Rose, J. Han, and M. H. Ginsberg, “α4 integrins and the immune response,” Immunological Reviews, vol. 186, pp. 118–124, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Kim, F. Ye, and M. H. Ginsberg, “Regulation of integrin activation,” Annual Review of Cell and Developmental Biology, vol. 27, pp. 321–345, 2011. View at Google Scholar
  15. Y. Imai, M. Shimaoka, and M. Kurokawa, “Essential roles of VLA-4 in the hematopoietic system,” International Journal of Hematology, vol. 91, no. 4, pp. 569–575, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Alon and M. L. Dustin, “Force as a facilitator of integrin conformational changes during leukocyte arrest on blood vessels and antigen-presenting cells,” Immunity, vol. 26, no. 1, pp. 17–27, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. J. T. Yang, H. Rayburn, and R. O. Hynes, “Cell adhesion events mediated by α4 integrins are essential in placental and cardiac development,” Development, vol. 121, no. 2, pp. 549–560, 1995. View at Google Scholar · View at Scopus
  18. D. C. Anderson and T. A. Springer, “Leukocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1, and p150,95 glycoproteins,” Annual Review of Medicine, vol. 38, pp. 175–194, 1987. View at Google Scholar · View at Scopus
  19. A. Fischer, B. Lisowska-Grospierre, D. C. Anderson, and T. A. Springer, “Leukocyte adhesion deficiency: molecular basis and functional consequences,” Immunodeficiency Reviews, vol. 1, no. 1, pp. 39–54, 1988. View at Google Scholar · View at Scopus
  20. A. Etzioni, “Defects in the leukocyte adhesion cascade,” Clinical Reviews in Allergy and Immunology, vol. 38, no. 1, pp. 54–60, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. B. Petri, M. Phillipson, and P. Kubes, “The physiology of leukocyte recruitment: an in vivo perspective,” Journal of Immunology, vol. 180, no. 10, pp. 6439–6446, 2008. View at Google Scholar · View at Scopus
  22. A. D. Luster, R. Alon, and U. H. von Andrian, “Immune cell migration in inflammation: present and future therapeutic targets,” Nature Immunology, vol. 6, no. 12, pp. 1182–1190, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Phillipson, B. Heit, P. Colarusso, L. Liu, C. M. Ballantyne, and P. Kubes, “Intraluminal crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in the recruitment cascade,” Journal of Experimental Medicine, vol. 203, no. 12, pp. 2569–2575, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. Z. Shulman, V. Shinder, E. Klein et al., “Lymphocyte crawling and transendothelial migration require chemokine triggering of high-affinity LFA-1 integrin,” Immunity, vol. 30, no. 3, pp. 384–396, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. E. J. Park, A. Peixoto, Y. Imai et al., “Distinct roles for LFA-1 affinity regulation during T-cell adhesion, diapedesis, and interstitial migration in lymph nodes,” Blood, vol. 115, no. 8, pp. 1572–1581, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. C. V. Carman, “Mechanisms for transcellular diapedesis: probing and pathfinding by ‘invadosome-like protrusions’,” Journal of Cell Science, vol. 122, no. 17, pp. 3025–3035, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Nieminen, T. Henttinen, M. Merinen, F. Marttila-Ichihara, J. E. Eriksson, and S. Jalkanen, “Vimentin function in lymphocyte adhesion and transcellular migration,” Nature Cell Biology, vol. 8, no. 2, pp. 156–162, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Millán, L. Hewlett, M. Glyn, D. Toomre, P. Clark, and A. J. Ridley, “Lymphocyte transcellular migration occurs through recruitment of endothelial ICAM-1 to caveola- and F-actin-rich domains,” Nature Cell Biology, vol. 8, no. 2, pp. 113–123, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. C. V. Carman, P. T. Sage, T. E. Sciuto et al., “Transcellular diapedesis is initiated by invasive podosomes,” Immunity, vol. 26, no. 6, pp. 784–797, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Proebstl, M.-B. Voisin, A. Woodfin et al., “Pericytes support neutrophil subendothelial cell crawling and breaching of venular walls in vivo,” Journal of Experimental Medicine, vol. 209, no. 6, pp. 1219–1234, 2012. View at Publisher · View at Google Scholar
  31. J. R. Mora and U. H. von Andrian, “T-cell homing specificity and plasticity: new concepts and future challenges,” Trends in Immunology, vol. 27, no. 5, pp. 235–243, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Sigmundsdottir and E. C. Butcher, “Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking,” Nature Immunology, vol. 9, no. 9, pp. 981–987, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. T. A. Yednock, C. Cannon, L. C. Fritz, F. Sanchez-Madrid, L. Steinmann, and N. Karin, “Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin,” Nature, vol. 356, no. 6364, pp. 63–66, 1992. View at Publisher · View at Google Scholar · View at Scopus
  34. B. Engelhardt, M. Laschinger, M. Schulz, U. Samulowitz, D. Vestweber, and G. Hoch, “The development of experimental autoimmune encephalomyelitis in the mouse requires α4-integrin but not α4β7-integrin,” Journal of Clinical Investigation, vol. 102, no. 12, pp. 2096–2105, 1998. View at Google Scholar · View at Scopus
  35. M. Soilu-Hänninen, M. Röyttä, A. Salmi, and R. Salonen, “Therapy with antibody against leukocyte integrin VLA-4 (CD49d) is effective and safe in virus-facilitated experimental allergic encephalomyelitis,” Journal of Neuroimmunology, vol. 72, no. 1, pp. 95–105, 1997. View at Publisher · View at Google Scholar · View at Scopus
  36. P. S. Piraino, T. A. Yednock, S. B. Freedman et al., “Prolonged reversal of chronic experimental allergic encephalomyelitis using a small molecule inhibitor of α4 integrin,” Journal of Neuroimmunology, vol. 131, no. 1-2, pp. 147–159, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. N. Tubridy, P. O. Behan, R. Capildeo et al., “The effect of anti-α4 integrin antibody on brain lesion activity in MS,” Neurology, vol. 53, no. 3, pp. 466–472, 1999. View at Google Scholar
  38. D. H. Miller, O. A. Khan, W. A. Sheremata et al., “A controlled trial of natalizumab for relapsing multiple sclerosis,” New England Journal of Medicine, vol. 348, no. 1, pp. 15–23, 2003. View at Publisher · View at Google Scholar
  39. C. H. Polman, P. W. O'Connor, E. Havrdova et al., “A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis,” New England Journal of Medicine, vol. 354, no. 9, pp. 899–910, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. R. A. Rudick, W. H. Stuart, P. A. Calabresi et al., “Natalizumab plus interferon beta-1a for relapsing multiple sclerosis,” New England Journal of Medicine, vol. 354, no. 9, pp. 911–923, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Langer-Gould, S. W. Atlas, A. J. Green, A. W. Bollen, and D. Pelletier, “Progressive multifocal leukoencephalopathy in a patient treated with natalizumab,” New England Journal of Medicine, vol. 353, no. 4, pp. 375–381, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. B. K. Kleinschmidt-DeMasters and K. L. Tyler, “Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis,” New England Journal of Medicine, vol. 353, no. 4, pp. 369–374, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. G. Van Assche, M. Van Ranst, R. Sciot et al., “Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease,” New England Journal of Medicine, vol. 353, no. 4, pp. 362–368, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Lindå, A. Von Heijne, E. O. Major et al., “Progressive multifocal leukoencephalopathy after natalizumab monotherapy,” New England Journal of Medicine, vol. 361, no. 11, pp. 1081–1087, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. K. R. Carson, D. Focosi, E. O. Major et al., “Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project,” The Lancet Oncology, vol. 10, no. 8, pp. 816–824, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. E. O. Major, “Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies,” Annual Review of Medicine, vol. 61, pp. 35–47, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. B. Huggett, “How Tysabri survived,” Nature Biotechnology, vol. 27, no. 11, p. 986, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. G. Bloomgren, S. Richman, C. Hotermans et al., “Risk of natalizumab-associated progressive multifocal leukoencephalopathy,” New England Journal of Medicine, vol. 366, no. 20, pp. 1870–1880, 2012. View at Publisher · View at Google Scholar
  49. J. Foley, “Recommendations for the selection, treatment, and management of patients utilizing natalizumab therapy for multiple sclerosis,” The American journal of managed care, vol. 16, no. 6, supplement, pp. S178–S183, 2010. View at Google Scholar · View at Scopus
  50. R. Rudick, C. Polman, D. Clifford, D. Miller, and L. Steinman, “Natalizumab: bench to bedside and beyond,” Archives of Neurology. In press.
  51. D. H. Miller, T. Weber, R. Grove et al., “Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial,” The Lancet Neurology, vol. 11, no. 2, pp. 131–139, 2012. View at Publisher · View at Google Scholar